Breaking News

Tacrolimus ointment augments narrow-band UVB therapy for vitiligo

Tacrolimus ointment augments narrow-band UVB therapy for vitiligo

 
 

A randomized, double-blind, placebo-controlled, right/left comparative study evaluated the effect of narrow-band UVB (NB-UVB) therapy combined with tacrolimus ointment 0.1% in 40 patients with stable symmetrical vitiligo. The patients were treated on one side with tacrolimus ointment and the other side with vehicle ointment. Whole-body NB-UVB was used 2-3 times/week for at least 3 months. The Visitrak® morphometric device assessed the area of the vitiligo lesions. Of the 40 patients, 27 had a superior effect on the tacrolimus side (P = 0.005), a median decrease in target lesion area of 42.1 vs. 29% on the tacrolimus and placebo sites, respectively. The treatment effect and number of topical tacrolimus applications was correlated (P ...

 
to Continue Reading, Login Now (Free Access)
 

Please Login

 
 
  
 
 
If you are a registered user but you have forgotten your password, please click here
 
If you are not a registered user, please register here

return to breaking news list